Effect of Cyclooxygenase-2 (COX-2) Inhibitors on Prostate Cancer Cell Proliferation

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3923-3928

  Srinath, P ^a   Rao, P N Praveen ^a   Knaus, Edward E ^a   Suresh, M R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

COX 2 inhibitors; Cyclooxygenase; Isoxazoline; Prostate cancer

Indexed keywords

1,1 DICHLORO 2 (4 NITROPHENYL) 3 PHENYLCYCLOPROPANE; 2(5H) FURANONE 5 [3 (3 ACETOXYPHENYL) 4 (4 METHANESULFONYLPHENYL) 2(5H) FURANONE]; 2,3 DIMETHYL 5 (4 METHYLSULFONYLPHENYL) 4 PHENYL 4 ISOXAZOLINE; 3 (4 METHYLSULFONYLPHENYL) 4 PHENYL 5 TRIFLUOROMETHYLISOXAZOLE; 6 ETHOXY 3 (4 METHANESULFONYLPHENYL) 4 (4 FLUOROPHENYL)PYRAN 2 ONE; 6 ISOPROPYL 3 (4 METHANESULFONYLPHENYL) 4 PHENYLPYRAN 2 ONE; 6 METHOXY 3 (4 METHANESULFONYLPHENYL) 4 (4 FLUOROPHENYL)PYRAN 2 ONE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ELECTROSTATICS; HETEROCYCLIC COMPOUNDS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; RATS;

EID: 0345305255     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics CA. Cancer J Clin 48: 6-29, 1998.
2. Herschman HR: Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60: 281-319, 1991.
3. Simmons DL, Levy LV, Yannoni Y and Erikson RI: Identification of a phorbol ester repressible v-src-inducible gene. Proc Natl Acad Sci USA 86: 1178-1182, 1989.
4. Sheng HM, Shao JY, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
5. Kujubu DA, Flecher BS, Varnum BC, Lim RW and Hershman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3t3 cells encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 166: 12866-12872, 1991.
6. Liu X, Yao S, Kirschenbaum A and Levine AC: NS-398, a selective cyclooxgenase-2 inhibitor, induces apoptosis and down regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249, 1998.
7. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell 83: 493-501, 1995.
8. Krischenbaum A, Klausner AP, Lee L, Unger P, Yao S, Liu XH and Levine AC: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56: 671-675, 2000.
9. North GL: Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 35: 1638-1643, 2001.
10. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P and Vaigro-Wolff A: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
11. Habeeb AG, Rao PNP and Knaus EE: Design and synthesis of 4,5 diphenyl -4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem 44: 2921-2927, 2001.
12. Habeeb AG, Rao PNP and Knaus EE: Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methyl sulfonyl pharmacophores by an azido bioisostere. J Med Chem 44: 3039-3042, 2001.
13. Rahim MA, Rao PNP and Knaus EE: Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 12: 2753-2756 2002.
14. Rao PNP, Habeeb AG and Knaus EE: Design, syntheses and evaluation of novel 1,1-dihalo-2,3-diphenylcyclopropanes as potential cyclooxygenase-2 (COX-2) inhibitors with analgesic-antiinflammatory activity. Drug Dev Res 55: 79-90, 2002.
15. Rao PNP, Amini A, Li H, Habeeb AG and Knaus EE: 6-Alkyl, alkoxy or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 13: 2205-2209, 2003.
16. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt KM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY and Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors; identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365, 1997.
17. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I and Zamboni R: The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(SH)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9: 1773-1778, 1999.
18. Twentyman PR and Luscombe M A: Study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987.
19. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of bcl-2. J Biol Chem 275: 1397-11403, 2000.
20. Patti R, Gumired K, Reddanna P, Sutton LN, Phillips PC and Reddy CD: Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett 180: 13-21, 2002.
21. Jonnalagadda SS, Harr ET, Hamel H, Lin CM, Magarian RA and Day BW: Synthesis and biological evaluation of 1,1-dichloro-2,3-diarylcyclopropanes as antitubulin and breast cancer agents. Bioorg Med Chem 5: 715-722, 1997.
22. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE and Chen CS: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94: 1745-1757, 2002.